Vaxcyte says VAX-31 met all primary endpoints in pivotal Phase 3 OPUS-1 adult trial

Vaxcyte said topline results from the pivotal Phase 3 OPUS-1 trial of VAX-31, its 31-valent pneumococcal conjugate vaccine candidate, met all prespecified primary endpoints across the age groups studied versus Prevnar 20 and/or Capvaxive.

Detected & updated continuously · Source: Nebula